Introduction: Cholestasis in childhood is a rare clinical condition, yet a definitive diagnosis is crucial for initiating treatment of these curable diseases and preventing related morbidity and mortality. The most common cause of infant cholestasis is biliary atresia (25–40%), followed by monogenic cholestatic diseases (25%), metabolic diseases (20%), and cryptogenic cholestasis. This study focuses on assessing the clinical utility of next-generation sequencing (NGS) panels, including clinical exome sequencing and whole exome sequencing, in diagnosing cholestatic diseases when the etiology cannot be elucidated through conventional methods. Materials and Methods: We conducted a retrospective examination of pediatric patients who sought care at a single-center pediatric gastroenterology department between August 2020 and March 2022 and were diagnosed with cholestasis. A total of 36 patients underwent a thorough investigation to rule out infectious, toxic, metabolic, structural, chromosomal, and endocrine causes. Patients whose diagnoses were established through traditional investigations were excluded from the study. The remaining 14 patients underwent either whole exome sequencing or targeted NGS methods. Results: A definitive diagnosis was achieved for 12 patients, while 2 patients remained undiagnosed despite comprehensive genetic examinations. The most commonly encountered diseases in this cohort were progressive familial intrahepatic cholestasis, linked to mutations in the ABCB11, ATP8B1, and TJP2 genes, as well as Dubin-Johnson syndrome associated with ABCC2 mutations. NGS demonstrated a diagnostic accuracy of 85.7% in patients for whom a diagnosis could not be established through extensive traditional workup. Conclusion: NGS emerges as a valuable diagnostic tool in cases of cholestasis where traditional methods fall short in providing a definitive diagnosis. Moreover, our study unveiled three previously undocumented variants in the ABCB11 [c.1165G>C; p.(Ala389Pro) and c.783 + 1G>A] and ABCC2 [c.4246_4247del; p.(Lys1416ValfsTer46)] genes.

1.
Moyer
V
,
Freese
DK
,
Whitington
PF
,
Olson
AD
,
Brewer
F
,
Colletti
RB
, et al
.
Guideline for the evaluation of cholestatic jaundice in infants: recommendations of the north American society for pediatric gastroenterology, hepatology and nutrition
.
J Pediatr Gastroenterol Nutr
.
2004
;
39
(
2
):
115
28
.
2.
Fawaz
R
,
Baumann
U
,
Ekong
U
,
Fischler
B
,
Hadzic
N
,
Mack
CL
, et al
.
Guideline for the evaluation of cholestatic jaundice in infants: joint recommendations of the north American society for pediatric gastroenterology, hepatology, and nutrition and the European society for pediatric gastroenterology, hepatology, and nutrition
.
J Pediatr Gastroenterol Nutr
.
2017
;
64
(
1
):
154
68
.
3.
Balistreri
WF
,
Bezerra
JA
.
Whatever happened to “neonatal hepatitis”
.
Clin Liver Dis
.
2006
;
10
(
1
):
27
53
.
4.
Jacquemin
E
,
Hadchouel
M
.
Genetic basis of progressive familial intrahepatic cholestasis
.
J Hepatol
.
1999
;
31
(
2
):
377
81
.
5.
Balistreri
WF
,
Bezerra
JA
,
Jansen
P
,
Karpen
SJ
,
Shneider
BL
,
Suchy
FJ
.
Intrahepatic cholestasis: summary of an American association for the study of liver diseases single-topic conference
.
Hepatology
.
2005
;
42
(
1
):
222
35
.
6.
Nicastro
E
,
D'Antiga
L
.
Next generation sequencing in pediatric hepatology and liver transplantation
.
Liver Transpl
.
2018
;
24
(
2
):
282
93
.
7.
Richards
S
,
Aziz
N
,
Bale
S
,
Bick
D
,
Das
S
,
Gastier-Foster
J
, et al
.
Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of medical genetics and Genomics and the association for molecular pathology
.
Genet Med
.
2015
;
17
(
5
):
405
24
.
8.
Lipiński
P
,
Ciara
E
,
Jurkiewicz
D
,
Pollak
A
,
Wypchło
M
,
Płoski
R
, et al
.
Targeted next-generation sequencing in diagnostic approach to monogenic cholestatic liver disorders-single-center experience
.
Front Pediatr
.
2020
;
8
:
414
.
9.
Chen
HL
,
Li
HY
,
Wu
JF
,
Wu
SH
,
Chen
HL
,
Yang
YH
, et al
.
Panel-based next-generation sequencing for the diagnosis of cholestatic genetic liver diseases: clinical utility and challenges
.
J Pediatr
.
2019
;
205
:
153
9.e6
.
10.
Elzouki
AN
.
Alpha 1-antitrypsin deficiency and related liver disease
.
Saudi J Gastroenterol
.
1999
;
5
(
1
):
1
8
.
11.
Shagrani
M
,
Burkholder
J
,
Broering
D
,
Abouelhoda
M
,
Faquih
T
,
El-Kalioby
M
, et al
.
Genetic profiling of children with advanced cholestatic liver disease
.
Clin Genet
.
2017
;
92
(
1
):
52
61
.
12.
Togawa
T
,
Sugiura
T
,
Ito
K
,
Endo
T
,
Aoyama
K
,
Ohashi
K
, et al
.
Molecular genetic dissection and neonatal/infantile intrahepatic cholestasis using targeted next-generation sequencing
.
J Pediatr
.
2016
;
171
:
171
e74
.
13.
Karpen
SJ
,
Kamath
BM
,
Alexander
JJ
,
Ichetovkin
I
,
Rosenthal
P
,
Sokol
RJ
, et al
.
Use of a comprehensive 66-gene cholestasis sequencing panel in 2171 cholestatic infants, children, and young adults
.
J Pediatr Gastroenterol Nutr
.
2021
;
72
(
5
):
654
60
.
14.
Nicastro
E
,
Di Giorgio
A
,
Marchetti
D
,
Barboni
C
,
Cereda
A
,
Iascone
M
, et al
.
Diagnostic yield of an algorithm for neonatal and infantile cholestasis integrating next-generation sequencing
.
J Pediatr
.
2019
;
211
:
54
62.e4
.
You do not currently have access to this content.